Leqembi is an infusion therapy that targets and removes the beta-amyloid plaque that builds up in the brains of Alzheimer's ...

The new findings center on a subset of 22 participants who received amyloid-removing drugs the longest, on average eight ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

The delays in Alzheimer’s research is one example of how millions of dollars in research have been stalled as NIH grapples ...

Meanwhile, two similar drugs — lecanemab, or Leqembi, and donanemab, or Kisunla — did meet the US Food and Drug Administration’s bar and were approved to treat people with Alzheimer’s who ...